New Alzheimer’s drug rais­es hopes — along with ques­tions

The FDA has ap­proved Leqem­bi, the first dis­ease-mod­i­fy­ing treat­ment for ear­ly-stage Alzheimer’s and a pre­cur­sor con­di­tion, mild cog­ni­tive im­pair­ment. Medicare has said it will pay …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER